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PENILAIAN KAWALAN GLISEMIK MEMBANDINGKAN INOVATOR 
DENGAN GENERIK DOS TETAP GLIBENCLAMIDE/ METFORMIN 
DALAM KALANGAN PESAKIT DIABETES MELLITUS DI KLINIK 
PESAKIT LUAR 
ABSTRAK 
Ubat generik menyediakan alternatif yang lebih murah dan terbukti setara 
seperti ubat inovator melalui kajian bioekuivalens tetapi data mengenai keberkesanan 
dan keselamatan adalah terhad. Kajian ini bertujuan untuk menilai perbezaan dalam 
kawalan glisemik, pematuhan ubat, kesan sampingan dan keberkesanan kos antara 
tablet inovator dan generik dos tetap glibenclamide/metformin selepas bertukar dari 
administrasi bersama gliclazide dan metformin dan selepas bertukar antara satu sama 
lain.  Kajian prospektif rawak bersilang ini dijalankan dari September 2014 hingga 
Ogos 2015 di kalangan pesakit diabetes jenis 2 yang dirawat dengan dos stabil 
sekurang-kurangnya 240 mg gliclazide dan 1000 mg metformin. Mereka dibahagikan 
secara rawak kepada dua kumpulan. Kumpulan A menerima tablet inovator 
glibenclamide/metformin 2.5/500 mg (Glucovance®) manakala Kumpulan B 
menerima tablet generik glibenclamide/metformin 2.5/500 mg (Diamide®) selama 
12 minggu. Selepas 12 minggu, pesakit dalam Kumpulan A ditukar kepada generik 
sementara pesakit dalam Kumpulan B ditukar kepada inovator. Ujian asas seperti 
hemoglobin terglikosilat (HbA1c), kiraan pil, ‘Morisky Medication Adherence 
Scale’ (MMAS) dan bilangan episod hipoglisemia diukur. Ujian diulangi pada 
minggu ke-12 dan ke-24. Nisbah tambahan keberkesanan kos (ICER) dikira. Seramai 
84 pesakit (59.5% perempuan; 51.2% dalam Kumpulan A) dengan purata umur 
58.01 ± 7.87 tahun dan mempunyai diabetes selama 10 (IQR 9.75) tahun menyertai 
kajian ini. Tiada perbezaan yang signifikan antara kumpulan dalam ciri-ciri asas. 
 xiii 
 
Purata HbA1c dikurangkan dengan signifikan dalam kedua-dua kumpulan 
(Kumpulan A -0.76%, p<0.01 dan Kumpulan B -0.56%, p<0.01) dari minggu ke-0 
hingga minggu ke-12  tetapi meningkat dengan signifikan dalam kedua-dua 
kumpulan (Kumpulan A +0.39%, p<0.01 dan Kumpulan B +0.33%, p<0.01) dari 
minggu ke-12 hingga minggu ke-24. Walau bagaimanapun, tiada perbezaan 
diperhatikan antara dua kumpulan (p>0.05).  Pertukaran dari administrasi bersama 
gliclazide dan metformin ke dos tetap glibenclamide/metformin mengurangkan 
purata HbA1c (-0.30%, p<0.01) secara signifikan dari minggu ke-0 hingga minggu 
ke-24. Kedua-dua kaedah kiraan pil dan MMAS menunjukkan peningkatan secara 
signifikan dalam kepatuhan kepada ubat-ubatan  selepas bertukar kepada tablet 
inovator atau generik dos tetap glibenclamide/metformin (p<0.01). Selain itu, 
pematuhan Kumpulan B meningkat dengan signifikan, p<0.05 apabila ditukar dari 
generik kepada inovator glibenclamide/metformin. Tiada perbezaan signifikan dalam 
bilangan episod hipoglisemia selepas bertukar kepada dos tetap 
glibenclamide/metformin. Walau bagaimanapun, kurang episod hipoglisemia 
(p=0.03) didapati apabila ditukar dari generik kepada inovator 
glibenclamide/metformin dalam Kumpulan B. Enam pesakit mengadu mengantuk 
dengan penggunaan generik glibenclamide/metformin. Lebih ramai pesakit mencapai 
sasaran HbA1c ≤ 6.5% dengan tablet inovator berbanding generik (10.7% vs 1.2%, 
p<0.05). ICER menunjukkan tambahan sejumlah RM 282.95 diperlukan untuk 
merawat pesakit untuk mencapai sasaran HbA1c dengan generik 
glibenclamide/metformin. Kesimpulannya, pertukaran kepada inovator atau generik 
dos tetap glibenclamide/metformin meningkatkan kawalan glisemik serta pematuhan 
ubat dengan signifikan dan ditolerasi dengan baik. Generik glibenclamide/metformin 
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adalah terapeutik yang setara seperti inovator dalam kawalan glisemik tetapi rawatan 
dengan inovator adalah lebih kos efektif. 
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EVALUATION OF GLYCAEMIC CONTROL COMPARING ORIGINAL 
VERSUS GENERIC FIXED DOSE GLIBENCLAMIDE/METFORMIN 
TABLET AMONG DIABETES MELLITUS PATIENTS IN AN 
OUTPATIENT CLINIC 
ABSTRACT 
Generic drugs provide cheaper alternative and proven to be equal as 
originator drugs through bioequivalence but the data on the efficacy and safety were 
limited. This study aimed to evaluate the differences in glycaemic control, 
adherence, adverse events and cost-effectiveness between original and generic fixed 
dose glibenclamide/metformin after switched from gliclazide co-administered 
metformin and after interchanged from each other. This prospective randomized 
cross over study was conducted from September 2014 to August 2015 among type 2 
diabetes patients treated with stable dose of at least 240 mg of gliclazide plus 1000 
mg of metformin. They were randomly divided into two groups. Group A received 
original glibenclamide/metformin 2.5/500 mg tablets (Glucovance
®
) whereas Group 
B received generic glibenclamide/metformin 2.5/500 mg tablets (Diamide
®
) for 12 
weeks. After 12-week, patients in Group A were changed to generic while patients in 
Group B switched to original glibenclamide/metformin. Baseline glycosylated 
haemoglobin (HbA1c), pill count, Morisky Medication Adherence Scale (MMAS) 
and number of hypoglycaemic episodes were measured. The tests were repeated at 
12-week and 24-week. Incremental cost-effectiveness ratio (ICER) was calculated. 
Eighty four patients (59.5% females; 51.2% in Group A) with mean age of 58.01 ± 
7.87 years and had diabetes for 10 (IQR 9.75) years were included. Baseline 
characteristics were no significant difference between the groups. Mean HbA1c 
reduced significantly in both groups (Group A -0.76%, p<0.01 and Group B -0.56%, 
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p<0.01) from 0-week to 12-week but increased significantly in both groups (Group A 
+0.39%, p<0.01 and Group B +0.33%, p<0.01) from 12-week to 24-week. However, 
there was no difference between the groups (p>0.05). Nevertheless, the switch from 
gliclazide co-administered metformin to fixed dose glibenclamide/metformin 
reduced mean HbA1c (-0.30%, p<0.01) significantly from 0-week to 24-week. Both 
pill count and MMAS showed significant improvement in adherence after the switch 
to fixed dose glibenclamide/metformin regardless of original or generic (p<0.01). 
Besides, adherence improved significantly, p<0.05 when changed from generic to 
original glibenclamide/metformin in Group B. There was no significant difference in 
number of hypoglycaemic episodes after switched to fixed dose 
glibenclamide/metformin. However, significantly less episodes of hypoglycaemia 
(p=0.03) occurred when changed from generic to original glibenclamide/metformin 
in Group B. Six patients complained of drowsiness with generic 
glibenclamide/metformin. More patients achieved target HbA1c ≤ 6.5% with original 
compared to generic (10.7% vs. 1.2%, p<0.05). The ICER showed an additional RM 
282.95 was required to treat patient to achieve target HbA1c with generic 
glibenclamide/metformin. In conclusion, the switch to original or generic fixed dose 
glibenclamide/metformin improved glycaemic control and adherence significantly 
and well tolerated. Generic fixed dose glibenclamide/metformin was therapeutically 
equivalent as original in glycaemic control but treatment with original was more 
cost-effective.   
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Introduction 
Diabetes mellitus is a chronic illness that has become a pandemic that affected 382 
millions of people worldwide and the prevalence was estimated to increase to 592 
millions in 2035 (Aguiree, Brown et al. 2013). The increased in diabetes population 
was mainly attributed by population growth and aging. With the rising prevalence, 
the direct healthcare cost of diabetes has increased for those aged between 20 to 79 
years and was estimated to be USD 612 billions globally (International Diabetes 
Federation 2014). Majority of the people (80%) living with diabetes came from low- 
to middle-income countries (Aguiree, Brown et al. 2013).  With the rapid growth and 
development, the number of diabetes patients increased in Western Pacific region 
that comprised of the one third of the world diabetes mellitus population (Aguiree, 
Brown et al. 2013). Thus, Western Pacific region that consisted of Malaysia, China, 
Japan, Thailand, Korea, Australia, New Zealand and others had the highest number 
of diabetes patients in the world. Despite being the region with most people living 
with diabetes, the total health expenditure related to diabetes was only USD 101 
billions which was 16% of the total world healthcare expenditure for diabetes in 
2013 (International Diabetes Federation 2014).   
In Malaysia, the prevalence of type 2 diabetes had increased tremendously with the 
latest National Health and Morbidity Survey (NHMS) that was done in 2015 reported 
17.5% adults aged 18 and above had diabetes compared to 15.2% in 2011 (Institute 
for Public Health 2011, Institute for Public Health 2015). It was no longer disease of 
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the elderly as more young people were living with diabetes nowadays. The 
prevalence of diabetes for those age 20 to 40 years doubled from year 2006 to 2011. 
For example, for those age between 20 to 24, the prevalence of diabetes mellitus 
increased from 2.0% in 2006 to 4.9% in 2011 (Letchuman, Wan Nazaimoon et al. 
2010). In fact, recently 5.5% of those age 18 to 19 years were living with diabetes 
and the highest prevalence was among those aged 70 to 74 years that accounted for 
39.1% of diabetes population in Malaysia. Higher prevalence was observed in urban 
area (17.7%) compared to rural area (16.7%) but was not statistically significant 
(Institute for Public Health 2015). The increased in prevalence might be due to 
availability of variety of food, unhealthy diet and physical inactivity following the 
rapid growth in the country. Additionally, the diabetes patients increased in 
conjunction with higher prevalence of obesity. Malaysia being a developing 
economy country, has no national public health insurance scheme (OECD , 
Reinhardt and Cheng 2000). Majority of known diabetes patients (79.3%) seek their 
treatment in the Ministry of Health Malaysia healthcare facilities (Institute for Public 
Health 2015). Hence, with the rising prevalence, it would increase the economic 
pressure on healthcare budgets.  
The cost per person with diabetes was estimated to be USD 565.40 annually in 
Malaysia (Aguiree, Brown et al. 2013). On the other hand, local drug utilization 
study reported that the cost per patient per year was RM 3747.12 for ambulatory care 
diabetes patients in the public hospitals (Pharmaceutical Services Division 2014). 
This drug utilization study involved mostly tertiary hospitals and state hospitals that 
managed more complicated diabetes cases and 12.5% of patients suffered three or 
more comorbidities. The diabetes patients had multiple comorbids as diabetes 
mellitus is a progressive chronic illness that leads to microvascular and 
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macrovascular complications if poorly controlled (Stratton, Adler et al. 2000). With 
these complications, it had increased the cost of treatment for diabetes to as much as 
quadruple (Riewpaiboon, Pornlertwadee et al. 2007, Wang, Fu et al. 2009). For 
example, in Malaysia, the cost per patient per admission in government hospital for 
patients with diabetes foot or gangrene was seven times higher compared to the 
estimated annual cost per patient with diabetes alone (Zawiah 2007). Similarly, in 
China, the annual direct medical cost significantly increased more than double if the 
patient had both microvascular and macrovascular diseases compared to diabetes 
alone (Wang, Fu et al. 2009). Besides the increasing cost of treatment, the underlying 
comorbids would alter the quality of life and also the productivity of individuals 
living with diabetes that could indirectly affect the economic development. 
Therefore, it is essential to control diabetes and also treat with alternatives that are 
cost-effective.  
Intensive glycaemic control is important to decrease microvascular and 
macrovascular complications such as retinopathy, nephropathy, cardiovascular 
disease and stroke (Holman, Paul et al. 2008) that will decrease the cost of treatment. 
However, percentage of diabetes patients achieving target was unsatisfactory in 
Malaysia as there was a drop of about 50% when comparing year 2003 and 2008. In 
2003, 31.2% of patients achieved target glycosylated haemoglobin (HbA1c) of < 
6.5% whereas only 11.4% of patients achieved this target in 2008. The mean 
duration of diabetes patients in Malaysia was 11.5 years. As duration of diabetes was 
longer, the glycaemic control worsened significantly (Mafauzy, Hussein et al. 2011). 
Meanwhile, more patients (23.8%) in the primary healthcare clinics in Malaysia were 
achieving target HbA1c in 2012 as compared to 19.4% in 2009. This might due to 
the shorter duration of diabetes in the primary healthcare clinics that was median 
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duration of five years (Feisul and Azmi 2013). In addition, patients in the primary 
healthcare clinics might be less complicated diabetes cases. The landmark study, 
UKPDS reported that only 25% of patients had glycaemic control of less than 7% 
with monotherapy of either insulin, metformin or sulphonylurea over the nine years 
follow-up period (Turner, Cull et al. 1999). This finding suggested that majority of 
patients required more than one medication to achieve their glycaemic target.   
The Malaysian Clinical Practice Guideline (CPG) and various guidelines available 
worldwide recommended metformin as the first line oral antidiabetic agent for type 2 
diabetes mellitus (Colagiuri, Dickinson et al. 2009, International Diabetes Federation 
2012, Garber, Abrahamson et al. 2013, Ministry of Health Malaysia 2015, American 
Diabetes Association 2016). Metformin is a biguanide that reduces hepatic glucose 
output and increases the insulin sensitivity (DeFronzo, Barzilai et al. 1991, Johnson, 
Webster et al. 1993, Stumvoll, Nurjhan et al. 1995). If metformin therapy failed to 
achieve target glycaemic control after three to six months, guidelines suggested 
addition of second line agent ranging from oral antidiabetic agents (OADs) to 
insulin. The Malaysian CPG offered flexibility of sulphonylurea (SU), α-glucosidase 
inhibitor (AGI), dipeptidyl peptidase- 4 (DPP-4) inhibitor, glucagon-like peptide 1 
(GLP-1) agonist, glinides, thiazolidinedione (TZD), sodium glucose co-transporter-2 
(SGLT-2) inhibitor or insulin as second line agent (Ministry of Health Malaysia 
2015). On the other hand, joint guideline by the American and European associations 
did not suggested AGI or glinides in the guidelines but suggested addition of other 
classes of antidiabetic agents similar to Malaysian CPG (American Diabetes 
Association 2016). As insulin was available in injection, majority of patients were 
taking oral medication (79.3%) compared to insulin (53.6%) (Mafauzy, Hussein et al. 
2011). Besides the patients unwillingness to inject insulin, the physicians also 
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reluctant to initiate insulin when considering barriers like inconvenient treatment 
regimen as well as risk factors of hypoglycaemia with insulin therapy (Korytkowski 
2002).  
Sulphonylurea was usually prescribed as second line agent in Malaysia. Drug 
utilization study that used defined daily dose (DDD) as its measurement reported that 
the usage of sulphonylurea was as high as 34.73 DDD/1000 population in 2010 
(Pharmaceutical Services Division and Clinical Research Centre 2014). This 
translated to on average 3.5% of Malaysian populations were prescribed with 
sulphonylurea every day in a year. Moreover, in the primary healthcare facilities, 
sulphonylurea (56.9%) was the second most used antidiabetic agents after metformin 
(82.5%) (Feisul and Azmi 2013). This is the drug class of choice as it was 
inexpensive and had long term efficacy and safety profile (Holman, Paul et al. 2008). 
Furthermore, only limited choices of drugs were available in primary healthcare 
facilities as the doctors available were medical officers or family medicine specialist. 
Newer generation of drugs such as DPP-IV inhibitors could only be prescribed by 
consultants. Prospective study comparing addition of either sulphonylurea, DPP-4 
inhibitor, GLP-1 agonist or insulin to metformin monotherapy reported that 
sulphonylurea as second line therapy was equally effective in lowering the blood 
glucose and comparable in quality adjusted life year with other agents at lower cost 
(Zhang, McCoy et al. 2014). Besides, studies reported that the combination of 
sulphonylurea and metformin was the most cost-effective therapy as compared to 
TZD (Klarenbach, Cameron et al. 2011). It is oral medication and hence, surpasses 
fear of insulin injection among patients. In addition, combination of metformin and 
sulphonylurea targeted both insulin resistance and insulin deficiency (DeFronzo 
1999). Sulphonylurea is an insulin secretagogue that triggers insulin release from the 
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pancreatic beta cell. Examples of sulphonylurea are glibenclamide, gliclazide, 
glimepiride and glipizide (Rendell 2004). All the agents in this group were equally 
effective (Gangji, Cukierman et al. 2007). A previous randomized double blind 
controlled trial that involved 289 T2DM patients showed that the efficacy of 40 mg 
gliclazide was comparable with 2.5 mg glibenclamide with no difference in fasting 
plasma glucose (FPG) and 2-hour post prandial glucose (Baba, Nakagawa et al. 
1983). Addition of sulphonylurea to metformin further reduced HbA1c by 0.8% and 
more patients achieved target glycaemic control compared to metformin alone (36% 
vs. 25%) (Hermann, Scherstén et al. 1994, McIntosh, Cameron et al. 2011).  
Currently, the combination oral antidiabetic agents were available in the Ministry of 
Health medication list. Fixed dose original glibenclamide/ metformin combination 
therapy (Glucovance®) had been available in the formulary since 2007 (Ministry of 
Health Malaysia 2010, Lim, Lim et al. 2012). The use of this combination tablet in 
public healthcare facilities had increased more than doubled in 2010 to 2.0897 
DDD/1000 population as compared to 0.7034 DDD/1000 population in 2009 
(Minisitry of Health Malaysia 2011). In February 2014, the generic fixed dose 
glibenclamide/ metformin tablet (Diamide®) had replaced the original 
glibenclamide/ metformin tablet in government hospitals and health clinics as the 
price was cheaper.   
A multicentre, randomized, double-blind, three-arm parallel group trial reported 
greater HbA1c reduction with fixed dose glibenclamide/ metformin compared to 
metformin or glibenclamide monotherapy in type 2 diabetes patients who 
inadequately controlled with lifestyle intervention (Garber, Donovan Jr et al. 2003). 
Interestingly, lower dose of fixed dose glibenclamide/ metformin provided a 
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significant greater reduction of HbA1c than glibenclamide co-administered 
metformin (2.02% vs. 1.49%, p < 0.01). At the same time, adherence to 
glibenclamide/ metformin tablets was better as compared to glibenclamide co-
administered metformin (84% vs. 76%, p < 0.01) (Blonde, Wogen et al. 2003). The 
combination tablets provided convenience and enhanced patients’ adherence towards 
the medication (Cheong, Barner et al. 2008, Schernthaner 2010). This might be 
attributed to the number of tablets consumed by the patients that were reduced. In a 
retrospective database analysis of 1815 patients by Melikian et al., the patients’ 
adherence improved by 16% when converting from polytherapy to a single 
combination tablet (Melikian, White et al. 2002). 
A previous retrospective study found that the patients’ HbA1c was reduced 
significantly by 0.83% after six months of switching to lower dose of glibenclamide 
in fixed dose glibenclamide/ metformin tablets from gliclazide co-administered 
metformin therapy (10 mg/day of glibenclamide vs. 270 mg/day of gliclazide).  This 
study also concluded a significant reduction in cost of drug acquisition by 44% (Lim, 
Lim et al. 2012). Randomized controlled studies demonstrated that gliclazide and 
glibenclamide had similar efficacy in reducing fasting and two hours postprandial 
glucose as well as HbA1c in type 2 diabetes patients including the elderly (Harrower 
1991, Tessier, Dawson et al. 1994). Moreover, a meta analysis of 21 randomized 
controlled trials that were heterogeneous (I
2 
= 42.1%) reported that glibenclamide did 
not increase the risk of cardiovascular events, death and weight gain when comparing 
with other sulphonylureas. However, glibenclamide had a higher risk of 
hypoglycaemia (15.3%) as compared to gliclazide (6.8%) (Gangji, Cukierman et al. 
2007). The studies in the meta analysis involved comparison of glibenclamide 
monodrug to sulphonylurea and did not include the glibenclamide in combination 
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drug such as fixed dose glibenclamide/ metformin. A prospective randomized 
controlled trial demonstrated that fasting insulin concentration was lower with fixed 
dose glibenclamide/ metformin as compared with glibenclamide monotherapy 
(p=0.024) but there was a higher 2-hours post prandial insulin response with 
glibenclamide/ metformin (Garber, Donovan Jr et al. 2003). With less fasting insulin 
concentration in fixed dose glibenclamide/ metformin, the risk of hypoglycaemia 
might be lowered while the higher post prandial insulin response could lead to better 
glycaemic control. Furthermore, the use of fixed dose glibenclamide/ metformin 
tablet involved lower glibenclamide dose that might reduce the risk of 
hypoglycaemia caused by glibenclamide in the glibenclamide/ metformin tablets and 
enable further upward dose titration in future management. This in return could delay 
the introduction of third oral antidiabetic agent or insulin.   
Fixed dose glibenclamide/ metformin tablet was cheaper that gliclazide tablet and 
consequently had lower cost than gliclazide co-administered metformin regardless of 
original or generic. Hence, it had become common practice of switching to fixed 
dose glibenclamide/ metformin from gliclazide co-administered metformin in the 
healthcare facilities in the Ministry of Health, Malaysia. The price of original 
glibenclamide/ metformin 2.5/500 mg was RM 0.10 per tablet whereas generic 
glibenclamide/ metformin 2.5/500 mg was priced at RM 0.06 per tablet and both 
were cheaper as compared to generic gliclazide 80 mg that costed RM 0.14 per tablet 
and generic metformin 500 mg which priced at RM 0.08 per tablet (Ministry of 
Health Malaysia 2010). The cost of treatment for oral antidiabetic agents for patients 
treated with fixed dose glibenclamide/ metformin tablets (two tablets twice a day) 
was RM 0.40/ day and RM 0.24/ day for original and generic respectively whereas 
for patients treated with gliclazide 240 mg/day co-administered metformin 2000 
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mg/day, the cost was RM 0.74/ day, which was about two to three times more costly. 
As there were only retrospective data and small scale studies available to support the 
switch to fixed dose glibenclamide/ metformin therapy, it is important to conduct a 
prospective study to evaluate the efficacy and safety of the change in therapy. 
Even though generic fixed dose glibenclamide/ metformin tablet was bioequivalence 
to original and film-coated tablet, it might not have special particle formulation as 
the originator product. In the originator product, glibenclamide was designed in a 
range of particle sizes within a freely soluble metformin matrix. When using 
ANOVA to analyze the log transform value, there were statistically differences 
between generic and original glibenclamide component in term of area under the 
curve (p=0.0159) and maximum concentration (p=0.0059). However, there was no 
difference between the metformin component in the original and generic fixed dose 
glibenclamide/ metformin product in term of area under the curve and maximum 
concentration.  As this was a combination tablet, bioequivalence was based on 90% 
confidence interval of the whole tablet as a component over reference and allowed 
certain variation in the rate and extend of absorption in the limit of 0.80 – 1.25 to 
grant the generic drug as equivalence based on US FDA and Malaysia 
Bioequivalence Guideline (Ministry of Health Malaysia 2000). Hence, generic fixed 
dose glibenclamide/ metformin was bioequivalence to original glibenclamide/ 
metformin because the tablet as a whole was within the bioequivalence limit of 0.80 
to 1.25 (Yuen, Wong et al. 2008). Even though fixed dose glibenclamide/ metformin 
passed the bioequivalence study, it might be different in therapeutic equivalence as 
the original fixed dose glibenclamide/ metformin had special formulation and the 
variation of glibenclamide in the fixed dose tablet might lead to different therapeutic 
effect. Besides, the issues around non-therapeutic equivalence among bioequivalence 
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products were happened among the antiepileptic drugs such as phenytoin and 
carbamazepine as those drugs had narrow therapeutic index. The change to generic 
had cause breakthrough seizure and emergence of new adverse events (Van 
Paesschen, Hauman et al. 2009). It was advisible that epileptic patients maintain with 
the same brand of antiepileptic drugs regardless of original or generic. Therefore, it is 
important to evaluate whether the different between generic and originator product 
especially combination drug or narrow therapeutic index drug will lead to clinically 
significant impact on the efficacy and safety of the patients. Nevertheless, to the best 
of our knowledge, currently there was no study comparing the efficacy, adherence 
and adverse drug reactions between original and generic fixed dose glibenclamide/ 
metformin tablet product. 
 
1.2 Rationale of The Study 
Prevalence of diabetes mellitus had increased tremendously in conjuction with 
increased in number of population and aging. Diabetes mellitus was a progressive 
disease that complicated with microvascular and macrovascular complications. As 
the population aged, the duration of diabetes was longer and also associated with 
more complications that decreased the quality of life. Besides, the cost of treatment 
for diabetes was getting higher as more new generation antidiabetic drugs were 
available at higher price and treatment of diabetes also included treatment of 
complications. This implied economic pressure in healthcare since most of the 
patients seek treatment in the public healthcare facilities. As the result, there was a 
need for drug that was effective, safe and inexpensive.   
 11 
 
Generic drugs provided cheaper alternatives and most of the drugs in the Ministry of 
Health Malaysia were switched to generic once off patent. However, several studies 
showed that prescribers had poor perception towards generic drugs as compared to 
original counterparts. A local study conducted in Hospital Seberang Jaya, Penang 
had demonstrated that only 35.6% of prescribers had perception that generic drug 
was equivalence to original drug and 32.2% of prescribers agreed that generic drug 
was not adequately tested. Majority of the prescribers(86.4%) need more information 
regarding the efficacy and safety of generic drugs (Leong, Lim et al. 2013). Besides, 
more than half of the patients (52.6%) preferred original drugs and 28.5% of patients 
agreed that generics were less effective (Lim, Leong et al. 2014 ). A study conducted 
in US also stated that 23% of the physicians had negative perception towards the 
efficacy and half of them was concerned about the quality of generic drugs (Shrank, 
Liberman et al. 2011). Similarly, majority of patients in US did not prefer generic 
drugs (Shrank, Cox et al. 2009). 
Therefore, this study enables us to compare the efficacy of original and generic fixed 
dose glibenclamide/ metformin tablet.  So far there was no prospective study being 
conducted to compare the efficacy between original and generic fixed dose product 
in Malaysia and other countries. Generic fixed dose product might have different 
formulation as compared to its original counterpart that would affect the efficacy and 
safety of the drugs when used in patients. The rate of absorption in the patients might 
be altered due to underlying disease, organ dysfunction and concomitant 
medications. Bioequivalence study was done in healthy subjects and might not be 
enough to demonstrate therapeutic equivalence. Thus, therapeutic equivalence study 
comparing generic and original fixed dose glibenclamide/ metformin in T2DM 
patients could provide better evidence. Previous studies were retrospective and had 
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demonstrated significant greater reduction of HbA1c in fixed dose glibenclamide/ 
metformin combination compared to sulphonylurea co-administered metformin
 
(Blonde, Wogen et al. 2003, Lim, Lim et al. 2012). Since the study was retrospective, 
association of better glycaemic control with adherence following treatment with 
lower dose of fixed dose glibenclamide/ metformin was not captured. Hence, this 
study enables us to evaluate the adherence and the association with glycemic control. 
Additionally, in the previous retrospective study conducted in Malaysia, the cost of 
drugs was evaluated but the issues around adverse drug reactions were not included 
(Lim, Lim et al. 2012). This study can also evaluate the adverse drug reactions when 
changing from gliclazide co-administered with metformin to fixed dose 
glibenclamide/ metformin tablet and the difference between the original and generic 
arm. Adverse drug reactions are measures for safety of the drug. With this 
prospective study, the overall cost of the treatment that included cost to treat adverse 
drug reactions can be evaluated. The true cost-effectiveness of original and generic 
fixed dose glibenclamide/ metformin tablets can be evaluated.  
Confidence of prescribers and patients towards generic will increase if generic fixed 
dose glibenclamide/ metformin is comparable to original fixed dose glibenclamide/ 
metformin in terms of efficacy and safety. Besides, the combination drugs with less 
tablet counts may be a better option in the treatment of T2DM if the efficacy and 
adverse events when switch to fixed dose glibenclamide/ metformin tablets are 
comparable or better than gliclazide co-administered metformin therapy, as it may 
safe the overall treatment cost.  
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1.3 Objectives of This Study 
1.3.1 General Objective 
To assess the patients’ glycemic outcome, adherence and adverse drug reactions 
between original and generic fixed dose glibenclamide/ metformin tablet after 
switching from gliclazide co-administered with metformin and after interchanging 
from original to generic or generic to original. 
 
1.3.2 Primary Objective 
To compare the HbA1c level between original and generic fixed dose glibenclamide/ 
metformin tablet. 
1.3.3 Secondary Objectives 
1) To evaluate the difference in HbA1c level after switching from gliclazide co-
administered metformin to fixed dose glibenclamide/ metformin. 
2) To compare the patients’ adherence to medication before and after switching 
from gliclazide co-administered with metformin to fixed dose glibenclamide/ 
metformin tablet. 
3) To determine the adverse drug reactions including patients reported 
hypoglycaemia and weight change after switching from gliclazide co-
administered with metformin to fixed dose glibenclamide/ metformin tablet. 
4) To compare the cost effectiveness between patients under generic and original 
fixed dose glibenclamide/ metformin tablet group. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Overview 
A systematic literature search was conducted using electronic databases that 
consisted of ProQuest, Science Direct, Wiley Online Library and Pubmed. Relevant 
articles from year 1984 to 2015 were identified. Text word, MESH terms and 
keywords for the search were “diabetes mellitus” or “diabetes mellitus type 2”or 
“diabetes mellitus type II” combined with “glyburide” or “glibenclamide”, 
“glyburide/metformin” or “glibenclamide/metformin”, “metformin” and 
“glibenclamide” or “glyburide” or “gliclazide” or “combination tablet” or “generic” 
or “original”. In addition, further search was carried out using text word and MESH 
terms of “diabetes mellitus” or “diabetes mellitus type 2” in combination with 
“glyburide/metformin” or “glibenclamide/metformin” and “gliclazide” or “generic” 
and “original”. As for the adherence of the antidiabetic agents, the search included 
keywords of “diabetes mellitus” and “adherence” or “compliance” or “combination 
tablet”. Only English language articles were filtered for literature review. Besides, 
additional search of the references of the articles were also done. All the abstracts 
were reviewed and appropriate full articles were critically appraised. If there was 
abundance of abstracts that were almost similar especially on review article, 
systematic review and meta-analyses, the latest version was selected.  
 
 
 
 15 
 
2.2 Type 2 Diabetes Mellitus (T2DM)- Pathophysiology 
Understanding the pathophysiology of a disease is utmost important for the 
management of the disease. As the result, to treat type 2 diabetes mellitus (T2DM) 
effectively, pathophysiology of this disease was discussed so that treatment was 
targeted to the mechanism that was responsible to this disease. 
Over the decades, two major metabolic defects namely ß-cell dysfunction and insulin 
resistance in the liver and muscle have been the main causes of T2DM (Buchanan 
2003). In fact, the pancreatic ß-cell failure occurred earlier before T2DM was 
diagnosed (DeFronzo 2009). However, there was a paradigm shift from triumvirate 
to ominous octet as the pathophysiology of T2DM expanding from ß-cell failure and 
insulin resistance in the liver and muscle to α-cell, gastrointestinal hormones, kidney, 
fat cells and brain (Figure 2.1) (DeFronzo 2010).  
    
Figure 2.1: Pathophysiology of type 2 diabetes mellitus 
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2.3 Guidelines for the Treatment of T2DM  
There were various guidelines for the treatment of T2DM in the world. However, all 
these guidelines had a similarity that metformin was the first line agent (Inzucchi, 
Bergenstal et al. 2012, Garber, Abrahamson et al. 2013, American Diabetes 
Association 2015, Ministry of Health Malaysia 2015). Metformin was the drug of 
choice as it is inexpensive and has durable efficacy and safety as well as robust 
evidence of cardiovascular safety (Holman, Paul et al. 2008, Selvin, Bolen et al. 
2008).  
In Malaysia, the Clinical Practice Guideline (CPG) was recently updated and 
published in November 2015. Unlike the previous CPG that had one treatment 
algorithm, the recent CPG recommended three types of treatment algorithm that 
consisted of treatment algorithm for newly diagnosed T2DM, patients on clinic 
follow-up and specific patient profiles (Ministry of Health Malaysia 2009, Ministry 
of Health Malaysia 2015). The treatment algorithm for newly diagnosed T2DM was 
almost the same as recommendation for patients on clinic follow-up. The difference 
was the newly diagnosed algorithm had additional column for HbA1c < 6.5% that 
recommended lifestyle interventions such as exercise and diet. This algorithm 
suggested addition of metformin or either one of these drug classes, namely glinides, 
α-glucosidase inhibitor (AGI) or dipeptidyl peptidase- 4 (DPP-4) inhibitor if post 
prandial blood glucose was more than 11 mmol/l. Specific patient profiles treatment 
algorithm were divided into five profiles namely normal weight, overweight, obese, 
increase risk of hypoglycaemia and chronic kidney disease (CKD) stage three 
onwards. This algorithm provided a more specific guideline by suggesting definite 
class of drug after metformin monotherapy failed. It was tailored to certain patients’ 
characteristics as compared to previous guideline that was more generalizable. 
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Hence, it might aid in faster decision making when choosing the appropriate 
treatment for the patients.  
Metformin was still the preferred first line agent for all three treatment algorithm 
when HbA1c fell between 6.5% to <7.5% except for CKD stage four and five, 
metformin was contraindicated. If the patient was unable to tolerate metformin, other 
agent such as sulphonylurea (SU), α-glucosidase inhibitor (AGI), dipeptidyl 
peptidase- 4 (DPP-4) inhibitor, glinides, glucagon like peptide-1 (GLP-1) agonist, 
thiazolidinedione (TZD) or sodium glucose co-transporter-2 (SGLT-2) inhibitor can 
also be considered as first line second line agent (Ministry of Health Malaysia 2015). 
The recent Malaysian CPG was more aggressive as smaller range of HbA1c in the 
algorithm and third agent was suggested to be added in when the HbA1c fell between 
8.5% to 10% (Ministry of Health Malaysia 2015). Previous CPG suggested larger 
range of HbA1c as monotherapy of oral antidiabetic agent (OAD) when HbA1c was 
between 6.5% to < 8.0% and dual therapy when HbA1c was 8.0% to 10% (Ministry 
of Health Malaysia 2009). Besides, recent CPG recommended earlier intervention 
such as addition of second agent was suggested after three months if the HbA1c 
target was not achieved.  Meanwhile previous CPG recommended intervention to be 
done after three to six months if glycaemic control was not achieving the target. This 
might be due to the availability of different classes of OAD and also early intensive 
glycemic control would provide long term benefit in reducing the relative risk of 
microvascular and macrovascular complications (Holman, Paul et al. 2008). 
If the target HbA1c was not achieved after three months with dual therapy, triple 
therapy was recommended. The recent Malaysian CPG recommended that oral agent 
could be added as third line as well as option of adding insulin unlike the previous 
guideline that suggested addition of insulin if dual therapy failed to achieve target 
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HbA1c. This might due to the availability of newer class of OAD. The updated 
guideline was similar to the American and European professional or regulatory 
organizations as there was option of addition of third oral agents. (Ministry of Health 
Malaysia 2009, Inzucchi, Bergenstal et al. 2012, Garber, Abrahamson et al. 2013, 
Ministry of Health Malaysia 2015).  
American Diabetes Association (ADA) recently updated its guideline and there was 
no difference with the guideline in 2015 (American Diabetes Association 2016). 
Joint guideline by the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) suggested that if the individualized 
target HbA1c was not met after three months, second line agent such as 
sulphonylurea, DPP-4 inhibitor, GLP-1 agonist, SGLT-2 inhibitor or insulin could be 
added (American Diabetes Association 2015). The guideline by ADA/EASD did not 
have the range of HbA1c as it focused on patient centred approach where target 
HbA1c was individualized. The Malaysian CPG also suggested the combination 
therapy of metformin with the same drug as the recommendation of American and 
European counterparts if the patient’s HbA1c level was > 6.5% after three months of 
monotherapy or the HbA1c level was between 7.5% to <8.5% during the diagnosis of 
diabetes with additional options of AGI and glinides. However, in the specific patient 
profiles algorithm, insulin was only suggested as fourth line (Ministry of Health 
Malaysia 2015). This might due to consideration of weight, risk of hypoglycemia and 
also patients’ preference of oral agents over insulin injection.  
Similar to Malaysian CPG, the American Association of Clinical Endocrinologists 
(AACE) also recommended that metformin was the first line agent for patients with 
newly diagnosed T2DM or mild hyperglycemia with HbA1c < 7.5%, but it was 
contraindicated in advance renal impaired patients. Alternatives to metformin 
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suggested by the AACE was same as the options suggested in latest Malaysian CPG. 
(Garber, Abrahamson et al. 2013). Both guidelines were more flexible as all classes 
of OAD were included in the guidelines and provided options that could be 
considered as first line if the patient was unable to tolerate metformin. AACE also 
recommended a larger option of second line agent if the patient failed to achieve 
target HbA1c with metformin alone or if diagnosed with HbA1c > 7.5%.  The 
options included all OADs or insulin as recommended by ADA as well as 
colesevelam, dopamine receptor agonist such as bromocriptine mesylate or AGI. 
AACE only recommended addition of insulin in patient with HbA1c > 8% on two or 
more OADs or patients with entry HbA1c > 9% due to consideration of few factors 
such as risk of hypoglycemia, patient’s motivation, underlying co-morbidities as well 
as patient well being (Garber, Abrahamson et al. 2013). 
All the latest guidelines recommended several OADs classes and insulin as the 
second line when the patients failed to achieve target of glycaemic control with 
metformin monotherapy (Garber, Abrahamson et al. 2013, American Diabetes 
Association 2015, Ministry of Health Malaysia 2015). There was no consensus that 
recommended a definite class of drug as the second line and provided the flexibility 
to the healthcare professionals except for the recent updated Malaysian CPG that 
added of specific patient profiles treatment algorithm (Ministry of Health Malaysia 
2015). This specific patient profiles treatment algorithm suggested DPP-4 inhibitor 
as second line agent as it was weight neutral. However, for overweight and obese 
patients, SGLT-2 inhibitor and GLP-1 analogue were recommended respectively. 
Even though, the updated CPG provided convenience in deciding the second or third 
line agent, consideration of the availability and cost of drug was still needed. The 
GLP-1 analogue and SGLT-2 inhibitor were not available in the Malaysian 
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government essential drug list and they were also very expensive (Ministry of Health 
Malaysia 2010). 
With the diverse guidelines, the definite glycaemic target remained controversial as 
different guidelines recommended different HbA1c target ranging from ≤ 6.5% 
(Garber, Abrahamson et al. 2013, Ministry of Health Malaysia 2015) to < 7% 
(American Diabetes Association 2015). The recent Malaysian CPG still maintained 
with glycaemic target of ≤ 6.5% in general but there was addition of ranges of target 
HbA1c like ADA/EASD guideline. Irrespective of the variation in the recommended 
glycaemic target among different guidelines, the best glycemic target should be 
individualized and consider patients underlying comorbidities, duration of diabetes, 
life expenctancy and also risk of hypoglycemia. Treatment of T2DM should 
incorporate patient-centric approach, treat to target and to avoid hypoglycemia. The 
recent Malaysian CPG considered these factors and suggested for younger and 
healthier patients with low risk of hypoglycemia, tighter target of 6.0%-6.5% was 
recommended whereas looser target of 7.1%-8.0% was recommended for elderly, 
patients with co-morbidities (coronary disease, heart failure, renal failure, liver 
dysfunction) or hypoglycemia prone patients (Inzucchi, Bergenstal et al. 2012, 
Ministry of Health Malaysia 2015).  
 
2.4 The Diabetes Control 
A previous cross sectional observational study conducted in Malaysia namely 
DiabCare Malaysia 2008 reported that as the duration of diabetes increased, 
glycaemic control deteriorated as mean HbA1c increased significantly (p<0.001). 
The mean HbA1c was reported as  7.32 ± 1.5% if the duration of diabetes was less 
 21 
 
than a year and it subsequently raised to above 8% as diabetes was longer with 8.34 
± 2.1%, 8.47 ± 1.9% and 8.83 ± 1.9% for the duration of 1-5 years, > 5-10 years and 
more than 10 years respectively. Only minority patients (11.4%) achieved glycaemic 
control of less than 6.5% as recommended by the Malaysian CPG (Ministry of 
Health Malaysia 2009). Besides, only 22% of the patients achieved HbA1c < 7% as 
of the ADA target as compared to 41% in 2003 (Mafauzy 2006, American Diabetes 
Association 2011). The blood glucose control deteriorated over the years with mean 
HbA1c of 8.66 ± 2.09% reported in DiabCare 2008 as compared to 7.80 ± 2.2% in 
2003 (Mafauzy, Hussein et al. 2011).  
Another cross sectional study conducted in a tertiary hospital in Malaysia that 
included T2DM patients aged 18 years and above and on diabetic medication for at 
least 3 months, also reported that only 17.4% (95% CI, 13.7-21.1%) of patients 
achieved target HbA1c of < 6.5% based on patients medical records. The main aim 
of this study was to assess patients adherence based on self reporting questionnaire. 
The mean age of the patients was 60.3 ± 10.3 years and the mean duration of T2DM 
was 13.2 ± 8.9 years. More than half of the patients (56.5%) were taking six to 10 
type of drugs with 76.5% of patients taking more than one antidiabetic agent and 
49.9% of patients injecting insulin. Metformin was the most commonly used 
antidiabetic agent (68.6%), followed by gliclazide (42.5%) (Chua and Chan 2011). 
Similar to DiabCare 2008, duration of diabetes  also affected the glycemic control 
besides adherence and use of complementary medicines (Chua and Chan 2011, 
Mafauzy, Hussein et al. 2011). The patients who were adherence to medications 
[p=0.035, OR 2.0 (1.1-3.7)], using complementary medicines [p<0.01, OR 0.4 (0.2-
0.8)] and those who had shorter duration of T2DM ≤10 years [p<0.01, OR 2.3 (1.2-
4.3)] were more likely to achieve target HbA1c (Chua and Chan 2011). These 
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findings had demonstrated that majority of patients were not achieving the targets 
even though on diabetes treatment. Besides, this was a single center survey study and 
the adherence was based on self-report that might over reporting. Therefore, 
reassessment of current practice plus measures such as addition or alteration of 
drugs, patients’ empowerment and education as well as adherence should be 
instigated. 
The glycaemic control in European countries and United Kingdom was reported to 
be better than Malaysia in the retrospective prevalence based study, CODE-2 that 
collected data from November 1998 to May 1999. The CODE-2 study consisted of 
seven countries in Europe and United Kingdom whereas the DiabCare 1998 was a 
cross sectional study from 10 centres in Malaysia. The mean HbA1c in CODE-2 
study was 7.5% whereas in DiabCare 1998, the mean HbA1c was 8.4%. The 
percentage of patients achieving HbA1c ≤ 6.5% was 31% in CODE-2 study (Liebl, 
Mata et al. 2002, Mafauzy 2006). This was more than doubled of the amount of 
patients in Malaysia as only 14% of patients achieved HbA1c < 6.5% in DiabCare 
1998. The patients in Malaysia was younger (56 ± 11.7 years) but had longer 
duration of diabetes (11 ± 7.4 years) and this might be the factor leading to poorer 
HbA1c control in the Malaysian study as compared to the patients in CODE-2 (mean 
duration of diabetes = 9.3 years; mean age = 69.5 years) (Mafauzy 2006). This was 
consistent to the disease progression over the duration of diabetes. In CODE-2 study, 
59% of the patients were on OADs and 24% on insulin alone or in combination with 
oral agents. However, patients on insulin alone or in combination with other drug had 
poorer glycemic control (mean HbA1c 8.1%) as compared to OADs (mean HbA1c 
7.5%) or diet and exercise alone (mean HbA1c 6.7%). Insulin might be added to 
maintain adequate glycaemic control especially for those with longer duration of 
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diabetes (Jönsson 2002). Meanwhile, for DiabCare 1998, there was no information 
on the drug use specifically for Malaysia but there was information based on 
grouping of six Asian countries. Majority of the patients were on OADs (81%) and 
only 6% of patients were on diet and 19% were on insulin with or without OADs. 
More than half (52%) of the patients were on oral combination therapy and more 
patients were taking SU (35%) than biguanide (12%) (Chuang, Tsai et al. 2002). 
Most of the patients required combination therapy as they were unable to achieve 
target HbA1c with monotherapy.  
On the other hand, in the United States, data from National Health and Nutrition 
Examination Survey (NHANES) was used to determine the prevalence, treatment 
and management of diabetes. Approximately half of the diabetes patients (50.9%) 
achieved HbA1c of < 7% from 1999 to 2006 (Cheung, Ong et al. 2009). Contrary to 
Malaysia, HbA1c improved over the years in the United States with 7.82% in 1999 
to 2000 and it dropped to 7.47% and 7.15% in 2001 to 2002 and from year 2003 to 
2006 respectively (Koro, Bowlin et al. 2004, Hoerger, Segel et al. 2008, Cheung, 
Ong et al. 2009). The improvement in glycaemic control in the United States might 
be attributed to awareness campaigns organized by ADA and also availability of 
multiple drugs. This might be ideal as it was almost achieving the target of HbA1c < 
7% as recommended by ADA and further reduction of glycaemic control might not 
show additional benefit to cardiovascular outcome (Skyler, Bergenstal et al. 2009).  
 
2.5 Second Line Agent 
In the UKPDS study, after nine years of follow-up in the intensive arm, only 25% of 
patients achieved HbA1c < 7% with monotherapy of either metformin, sulphonylurea 
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or insulin (Turner, Holman et al. 1998). This suggested that majority of patients 
require more than one medication to achieve their glycaemic target. There was no 
consensus that recommended a definite class of drug as the second line and provided 
the flexibility to the healthcare professionals. Thus, drug that was efficacious, safe 
and economical should be suggested as the choice for second line agent considering 
the rising prevalence in T2DM (Aguiree, Brown et al. 2013) and its impact towards 
economic burden (International Diabetes Federation 2014).  
The latest drug class, SGLT-2 inhibitor targeted a different pathway that was 
inhibiting the reabsorption of glucose in the kidney independent of insulin (Bays 
2009, Brunton and Reid 2014). Dapagliflozin by Astra Zaneca® was the first SGLT-
2 inhibitor approved by the European Medicines Agency (EMA) at the end of 2012 
and it was launched in Malaysia at early 2014 (Haas, Eckstein et al. 2014). On the 
other hand, canagliflozin was the first SGLT-2 inhibitor granted marketing in the 
United States as dapagliflozin had safety concern on increased risk of bladder and 
breast cancer (Burki 2012). The evidence on the safety of this drug class was still 
ongoing (Neal, Perkovic et al. 2013). Recently,  13 episodes of euglycaemic diabetic 
ketoacidosis and ketosis were reported among type 1 diabetes and type 2 diabetes 
patients taking SGLT-2 inhibitors (Peters, Buschur et al. 2015).  Indeed, EMA and 
US Food and Drug Administration (FDA) were following the post-marketing 
surveillance on its cardiovascular, renal safety and cancer risk (Haas, Eckstein et al. 
2014). In Malaysia, the use of SGLT-2 inhibitor was limited to the private sector as it 
was not included in the government essential drug list. Although the Malaysian CPG, 
AACE and ADA recommended addition of SGLT-2 inhibitor as second line agent, 
the International Diabetes Federation (IDF) did not recommend the use of SGLT-2 
